Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Other Non Operating Income of $1000.0 for Q1 2026, up 100.43% year-over-year from $498.92 in Q1 2025, and up 100.06% quarter-over-quarter from -$1.7 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Other Non Operating Income history runs 17 years deep, the most recent figure standing at $1000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 100.43% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $232000.0 (up 136.94% YoY), while the FY2023 annual figure was $542000.0, up 125.19% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $1000.0, up from -$1.7 million in the prior quarter.
- The five-year high for Other Non Operating Income was $1.7 million in Q2 2025, with the low at -$1.9 million in Q2 2022.
- The 5-year median for Other Non Operating Income is -$101500.0 (2022), against an average of -$184000.0.
- Peak annual rise in Other Non Operating Income reached 543.92% in 2025, while the deepest fall reached 8668.42% in 2025.
- Lineage Cell Therapeutics' Other Non Operating Income stood at $398000.0 in 2022, then tumbled by 100.5% to -$2000.0 in 2023, then plunged by 850.0% to -$19000.0 in 2024, then plunged by 8668.42% to -$1.7 million in 2025, then jumped by 100.06% to $1000.0 in 2026.
- Business Quant data shows LCTX's Other Non Operating Income at $1000.0 in Q1 2026, -$1.7 million in Q4 2025, and $219000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 664,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | -1.67 Mn |
| Sep 30, 2025 | 219,000.00 |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | -231,000.00 |
| Dec 31, 2024 | -19,000.00 |
| Jun 30, 2024 | -378,000.00 |
| Mar 31, 2024 | -354,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | -497,000.00 |
| Mar 31, 2023 | 457,000.00 |
| Dec 31, 2022 | 398,000.00 |
| Sep 30, 2022 | -475,000.00 |
| Jun 30, 2022 | -1.89 Mn |
| Mar 31, 2022 | -184,000.00 |
| Dec 31, 2021 | 963,000.00 |
| Sep 30, 2021 | 393,000.00 |
| Jun 30, 2021 | 523,000.00 |